Furthermore, given the fact that AXL is involved in acquired drug resistance of many solid tumors including NSCLC, leukemia, breast cancer, ovarian cancer, and cancers of the gastrointestinal tract [18], development of a selective AXL inhibitor will help the successful management of advanced cancer patients with acquired resistance to targeted therapies. Here, AXL is linked to non-small cell lung carcinoma.